Copper oxide nanoparticles function as antineoplastic agents in uterine cancer cell lines

Area of Science:

• Nanomedicine
• Materials Science
• Oncology

Background:

• Uterine corpus cancer is a significant cause of death in women.
• Chemotherapeutic resistance, particularly to platinum-based drugs, limits treatment options.
• Novel therapeutic strategies are needed for advanced uterine cancers.

Purpose of the Study:

• To evaluate the anti-neoplastic activity of copper oxide nanoparticles (CuO NPs) against endometrial and cervical cancer cell lines.
• To characterize CuO NPs and assess their effects on cancer cell viability, apoptosis, migration, and reactive oxygen species.
• To investigate the impact of genetic mutations on cancer cell response to CuO NPs.

Main Methods:

• Characterization of CuO NPs using TEM, SEM, EDS, DLS, and LDV.
• Assessment of cell viability (IC50 values), apoptosis, migration, and reactive oxygen species in multiple cancer cell lines.
• CRISPR-Cas9 gene editing to introduce specific mutations in a cervical cancer cell line.

Main Results:

• CuO NPs exhibited varying efficacy across different endometrial cancer cell lines, with IC50 values ranging from 1.028 to 73.62 ug/mL.
• CuO NPs induced cell line-dependent differences in apoptosis, oxidation potential, and migration.
• Genetically modified cervical cancer cells showed altered redox potential but no significant changes in apoptosis or migration.

Conclusions:

• Copper oxide nanoparticles demonstrate cancer cell-specific anti-neoplastic effects, influenced by cancer stage and genetic makeup.
• CuO NPs hold promise as a potential targeted therapy for uterine and cervical cancers.
• Further research integrating colloid science and tumor microenvironment knowledge could lead to novel cancer treatments.